Gene fusions and gene variants associated with cancer

Patent metadata

Field	Value
Publication number	US-11746379-B2
Application number	US-201816103516-A
Country	US
Kind code	B2
Filing date	Aug 14, 2018
Priority date	Apr 17, 2013
Publication date	Sep 5, 2023
Grant date	Sep 5, 2023

Abstract

The disclosure provides gene fusions, gene variants, and novel associations with disease states, as well as kits, probes, and methods of using the same.

First claim

What is claimed:

1. A composition reaction mixture comprising a target nucleic acid and a set of primers that specifically hybridize to the target nucleic acid to flank a gene fusion, a recombinant thermostable polymerase, and dNTPs, wherein the set of primers specifically amplify a fusion between the KANK2 gene and the ALK gene comprising SEQ ID NO: 272, and wherein each primer is 15 to 40 nucleotides long and a deoxyribonucleic acid sequence comprising at least one deoxyuridine (dU) residue in place of a deoxythymidine residue.

2. The composition of claim 1 , additionally comprising one or more additional set of primers that specifically hybridize to one or more additional target nucleic acids to flank a gene fusion, wherein the additional set(s) of primers specifically amplify at least one fusion of two genes comprising one or more sequences selected from SEQ ID NOs: 1-328.

3. A kit comprising components:
i. a set of primers that specifically hybridize to a target nucleic acid to flank a gene fusion, wherein the set of primers specifically amplify a fusion between the KANK2 gene and the ALK gene comprising SEQ ID NO: 272, and wherein each primer is 15 to 40 nucleotides long and a deoxyribonucleic acid sequence comprising at least one deoxyuridine (dU) residue in place of a deoxythymidine residue,
ii. a recombinant thermostable polymerase, and
iii. a set of dNTPs.

4. The kit of claim 3 , additionally comprising one or more additional set of primers that specifically hybridize to a target nucleic acid to flank a gene fusion that specifically amplify at least one fusion of two genes comprising one or more sequences selected from SEQ ID NOs: 1-328.

5. The composition of claim 2 , wherein the set of primers specifically hybridize to at least one nucleic acid comprising a break point from sequences selected from SEQ ID NOs: 1-328.

Assignees

• Life Technologies Corp

Inventors

• Rhodes Daniel
• Sadis Seth
• Wyngaard Peter
• Khazanov Nikolay
• Bandla Santhoshi
• Tomilo Mark
• Eddy Sean
• Bowden Emma
• Li Jia

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• G16B20/20

  Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title